Merck Licenses China Cancer Drug
Merck agreed to pay SciBrunch Therapeutics 400 million upfront for global rights to an experimental cancer drug. This marks the latest licensing agreement between a US drugmaker and a Chinese biotech firm.
Xurve View
Insights:
Xurve View
Merck agreed to pay $400 million upfront to SciBrunch Therapeutics for global rights to an experimental cancer drug on Monday. The deal highlights a growing trend of United States drugmakers turning to China for early-stage oncology and immunology licensing agreements. Domestic biotechs frequently retain local commercial rights while partnering overseas for billions in milestone and royalty payments.
